AKYA Akoya Biosciences
- 3.800
- -0.020-0.52%
- 3.800
- 0.0000.00%
Akoya Biosciences News
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company, today announced that it will release financial results for the first quarter of
Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting With Case Studies Demonstrating Unprecedented Speed and Scale
MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company, today announced it will highlight case studies featuring its Spatial Biol
Akoya Biosciences(AKYA.US) Officer Sells US$37,242.75 in Common Stocks
$Akoya Biosciences(AKYA.US)$ Officer McKelligon Brian sold 7,500 shares of Common Stocks on Mar 20, 2024 at an average price of $4.9657 for a total value of $37,242.75.Source: Announcement What is sta
(SEC Amendment) Akoya Biosciences(AKYA.US) Officer Sells US$37,042.5 in Common Stocks
$Akoya Biosciences(AKYA.US)$ Officer McKelligon Brian sold 7,500 shares of Common Stocks on Mar 13, 2024 at an average price of $4.939 for a total value of $37,042.5.Source: Announcement What is state
Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider
Bringing End-to-End Spatial Biology Solutions to Life Sciences Researchers for Advanced Spatial Proteomics AnalysisWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecula
Akoya Biosciences(AKYA.US) Officer Sells US$37,035 in Common Stocks
$Akoya Biosciences(AKYA.US)$ Officer McKelligon Brian sold 7,500 shares of Common Stocks on Mar 13, 2024 at an average price of $4.938 for a total value of $37,035.Source: Announcement What is stateme
Akoya Biosciences (AKYA) Gets a Buy From Piper Sandler
Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Market Cap Dropped US$62m Last Week; Individual Investors Who Hold 49% Were Hit as Were Institutions
Key Insights The considerable ownership by private equity firms in Akoya Biosciences indicates that they collectively have a greater say in management and business strategy 53% of the business is he
Akoya Biosciences Is Maintained at Overweight by JP Morgan
Akoya Biosciences Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on Akoya Biosciences, Lowers Price Target to $10
Akoya Biosciences Price Target Raised to $7.50/Share From $7.00 by UBS
Akoya Biosciences Price Target Raised to $7.50/Share From $7.00 by UBS
Akoya Biosciences Is Maintained at Buy by UBS
Akoya Biosciences Is Maintained at Buy by UBS
Express News | Canaccord Genuity Reiterates Buy on Akoya Biosciences, Maintains $10 Price Target
Akoya Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 75.44% Canaccord Genuity → $10 Reiterates Buy → Buy 12/14/2023 — Guggenheim Initiates Coverage
Earnings Call Summary | Akoya Biosciences(AKYA.US) Q4 2023 Earnings Conference
The following is a summary of the Akoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call Transcript:Financial Performance:Akoya's Q4 2023 revenue hit $26.5 million and yearly revenue closed at $96.6 mil
Akoya Biosciences Inc (AKYA) Reports Record Q4 Revenue and Sets Positive 2024 Outlook
Recap: Akoya Biosciences Q4 Earnings
Akoya Biosciences (NASDAQ:AKYA) reported its Q4 earnings results on Monday, March 4, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsAkoya Biosciences beat estimated
Akoya Biosciences GAAP EPS of -$0.22 Beats by $0.06, Revenue of $26.5M Beats by $0.39M
Akoya Biosciences Sees 2024 Rev $114M-$118M >AKYA
Akoya Biosciences Sees 2024 Rev $114M-$118M >AKYA
Analysis
Price Target
No Data
